指南与共识白血病淋巴瘤

经典毛细胞白血病诊断与管理共识指南

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.
指南 / 共识 · Blood · 2016-11-30

毛细胞白血病是一种罕见血液恶性肿瘤,特征为全血细胞减少和易感染。该共识指南由毛细胞白血病基金会召开国际会议制定,旨在提供应答、复发和微小残留病检测的统一可重复标准,并推荐患者参与临床试验。

要点

  • 毛细胞白血病特征为全血细胞减少和显著感染易感性。
  • 需统一应答、复发和微小残留病检测的定义以比较临床试验结果。
  • 强烈推荐一线及尤其复发患者参与可用临床试验。

核心结论

  • 该共识指南为经典毛细胞白血病提供统一标准和框架,以指导当前管理并持续改善患者结局。

研究设计与样本

  • 毛细胞白血病基金会召开国际会议制定共识指南。

主要发现

  • 毛细胞白血病管理取得巨大进展,应答率高且生存改善,但复发和再治疗策略仍需研究。
  • 疾病及其有效治疗与免疫抑制相关。
  • 更多患者接受替代方案治疗,比较结果需就应答、复发和微小残留病检测方法达成普遍一致。

关键数值与推荐

  • 强烈推荐一线及尤其复发患者参与可用临床试验。
  • 制定国际公认、可重复的标准对评估和比较临床试验至关重要。

临床怎么用

  • 临床应使用共识提供的统一应答、复发和微小残留病检测定义。
  • 强烈推荐一线及复发患者参与可用临床试验。

局限性

  • 复发和再治疗的适当方法仍是持续研究领域。
  • 疾病及其有效治疗与免疫抑制相关。
  • 需继续研究优化严重感染风险的预防和管理。
  • 需组织评估微小残留病和复发治疗。
  • 需对日益增多的幸存者进行生活质量学术评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to re-treatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the first-line and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Grever MR, Abdel-Wahab O, Andritsos LA, et al. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. Blood. 2016. PMID: 27903528. doi:10.1182/blood-2016-01-689422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。